Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside ...

Before joining Investopedia, David Marino-Nachison was an editor at The Wall Street Journal focused mainly on daily markets and investing news. He also worked on The Journal’s publishing desk; as a ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Joe Ciolli Every time Joe publishes a story, you’ll get an ...